IN THE CLAIMS:

Cancel claims 38 and 44-46.

Amend claims 35, 36, 42, 43, 47-49 and 51 as follows:

35 (Amended) A pharmaceutical formulation for parenteral administration comprising a [pure] solid state Na^+, Li^+ or K^+ [alkaline] salt of the (-)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5,-dimethyl-2-pyridinyl)methyl]sulfinyl]-1*H*-benzimidazole as active ingredient, and a pharmaceutically acceptable carrier.

having m.p. 247-249 nmR data

36. (Amended) A pharmaceutical formulation for parenteral administration comprising a sterile injection solution comprising a [pure] solid state Na^+, Li^+ or K^+ [alkaline] salt of the (-)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5,-dimethyl-2-pyridinyl)methyl]sulfinyl]-1*H*-benzimidazole as active ingredient, and a pharmaceutically acceptable carrier in the form of a pharmaceutically acceptable solvent having a volume sufficient to effect a solution having a concentration of 0.1 to 10% by weight of the active ingredient.

42. (Amended) A method of inhibiting gastric acid secretion comprising the parenteral administration to a mammal including man in need of such treatment of a pharmaceutical formulation comprising a therapeutically effective amount of a [pure] solid state Na^+, Li^+ or K^+ [alkaline] salt of the (-)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5,-dimethyl-2-pyridinyl)methyl]sulfinyl]-1*H*-benzimidazole and a pharmaceutically acceptable carrier.

43. (Amended) A method for the treatment of gastrointestinal inflammatory disease comprising the parenteral administration to a mammal including man in need of such treatment of a